Edition:
United Kingdom

Anavex Life Sciences Corp (AVXL.OQ)

AVXL.OQ on NASDAQ Stock Exchange Capital Market

3.30USD
11 Dec 2017
Change (% chg)

-- (--)
Prev Close
$3.30
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
55,566
52-wk High
$6.63
52-wk Low
$3.03

Chart for

About

Anavex Life Sciences Corp. is a clinical-stage biopharmaceutical company. The Company is engaged in the development of differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental diseases, including drug candidates to treat Alzheimer's disease (AD), other central nervous system (CNS) diseases, pain... (more)

Overall

Beta: 1.01
Market Cap(Mil.): $177.54
Shares Outstanding(Mil.): 42.17
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 88.65 16.44
EPS (TTM): -- -- --
ROI: -- 2.35 10.62
ROE: -- 2.95 14.20

BRIEF-Anavex Life Sciences reports PK and PD data from Phase 2a trial of ANAVEX2-73

* Anavex Life Sciences reports PK and PD data from Phase 2a trial of ANAVEX2-73 in mild-to-moderate Alzheimer’s Disease patients

12 Oct 2017

BRIEF-Anavex reports Q3 loss per share of $0.09

* Q3 loss per share $0.09 Source text for Eikon: Further company coverage:

07 Aug 2017

Earnings vs. Estimates